AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29144240
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (music + sucrose)
Trial: 25990055
Drug: Pitavastatin calcium
RxNorm normalized name: PITAVASTATIN CALCIUM
DrugBank: Pitavastatin (DB08860)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pitavastatin calcium 2 mg/d for 8 weeks
Trial: 25990055
Drug: Pitavastatin calcium
RxNorm normalized name: PITAVASTATIN CALCIUM
DrugBank: Pitavastatin (DB08860)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pitavastatin calcium (both doses)
Trial: 23857975
Drug: Chemotherapy before
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy before radiation (CT1) - three cycles of cisplatin and etoposide before radiation
Trial: 23857975
Drug: Chemotherapy after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy after radiation (RT1) - same chemotherapy regimen after radiation
Trial: 16332659
Drug: Isoflavone-enriched cereal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflavone-enriched cereal bars (50 mg/d)
Trial: 11109512
Drug: felodipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: felodipine (10 mg)
Trial: 18297254
Drug: cilazapril (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cilazapril (5 mg)
Trial: 7964942
Drug: Hepatic arterial
RxNorm normalized name: Sus scrofa artery preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatic arterial floxuridine (FUDR) 0.30 mg/kg/d, leucovorin (LV) 15 mg/m2/d, dexamethasone (Dec) 20 mg total dose as a 14-day hepatic arterial infusion via an implantable pump alternating with 2 weeks of saline
Trial: 2891368
Drug: Temelastine 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temelastine 75 mg twice daily
Trial: 8733993
Drug: Terfenadine 60
RxNorm normalized name: terfenadine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terfenadine 60 mg twice daily
Trial: 24554791
Drug: Multimodal exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal exercise program (60-min class twice a week for 16 weeks)
Trial: 21427067
Drug: Venlafaxine 50
RxNorm normalized name: venlafaxine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine 50 mg 1 hour prior to oxaliplatin infusion and venlafaxine extended release 37.5 mg b.i.d. from day 2 to day 11
Trial: 17470165
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg sildenafil as needed
Trial: 17470165
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg paroxetine daily
Trial: 17470165
Drug: Squeeze technique
RxNorm normalized name: sodium bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Squeeze technique daily
Trial: 4072874
Drug: Quiniday, 1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quiniday, 1200 mg once daily
Trial: 4072874
Drug: Quinidine sulfate
RxNorm normalized name: Quinidine Sulfate
DrugBank: Quinidine (DB00908)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quinidine sulfate (Quinora, 300 mg four times daily)
Trial: 4072874
Drug: Quinidine sulfate
RxNorm normalized name: Quinidine Sulfate
DrugBank: Quinidine (DB00908)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quinidine sulfate (Quinidex Extentabs, 600 mg twice daily)
Trial: 29880162
Drug: 16 mg
RxNorm normalized name: escin 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg Dexamethasone IV drip
Trial: 29880162
Drug: 16 mg
RxNorm normalized name: escin 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg Dexamethasone subcutaneous injection
Trial: 29880162
Drug: Placebo (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (500 cc saline infusion)
Trial: 28654721
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of resin infiltration and bleaching
Trial: 18465244
Drug: Ranitidine bismuth
RxNorm normalized name: RANITIDINE BISMUTH CITRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine bismuth citrate (RBC) 400 mg b.d. plus amoxicillin 1 g b.d. and clarithromycin 500 mg b.d. (RAC group, n = 30)
Trial: 18465244
Drug: RBC 400
RxNorm normalized name: Ultratag RBC KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBC 400 mg b.d. plus moxifloxacine 400 mg o.d. and amoxicillin 1,000 mg b.d. (RAM group, n = 30)
Trial: 18465244
Drug: Esomeprazole 40
RxNorm normalized name: esomeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40 mg b.d. plus amoxicillin 1,000 mg b.d. plus clarithromycin 500 mg b.d. (EAC group, n = 30)
Trial: 10848858
Drug: Blue-hub needle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blue-hub needle (23 G) with local anaesthetic
Trial: 10848858
Drug: Green-hub needle
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Green-hub needle (21 G) with local anaesthetic
Trial: 22540912
Drug: Metformin alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin alone (1000 mg twice daily)
Trial: 22540912
Drug: Metformin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin plus rosiglitazone (4 mg twice a day)
Trial: 19709100
Drug: Polyphenon E
RxNorm normalized name: Polyphenon E
DrugBank: Sinecatechins (DB01266)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Polyphenon E ointment 10% (G(10%))
Trial: 19709100
Drug: Polyphenon E
RxNorm normalized name: Polyphenon E
DrugBank: Sinecatechins (DB01266)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Polyphenon E ointment 15% (G(15%))
Trial: 19709100
Drug: Vehicle (G(Veh))
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle (G(Veh))
Trial: 2643934
Drug: Intravenous clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous clonidine (2 micrograms/kg)
Trial: 3881263
Drug: Pentoxifylline (PTX)
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (PTX) 1,200 mg/day (Trental 400 t.d.s.)
Trial: 3881263
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid and dipyridamole (ASAD, 1,050 mg + 150 mg/day)
Trial: 30531477
Drug: PF-06372865 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06372865 2.5 mg twice daily
Trial: 30531477
Drug: PF-06372865 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06372865 7.5 mg twice daily
Trial: 28270181
Drug: Weekly paclitaxel-epirubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly paclitaxel-epirubicin (PE) regimen
Trial: 28270181
Drug: Tri-weekly 5-fluorouracil-epirubicin-cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tri-weekly 5-fluorouracil-epirubicin-cyclophosphamide (FEC) regimen
Trial: 19730966
Drug: Promethazine 6.25
RxNorm normalized name: DM 15/PROMETHAZINE 6.25MG/5ML SYRUP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Promethazine 6.25 mg iv
Trial: 9591489
Drug: Subcutaneous (s.c.)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (s.c.) gonadotropins
Trial: 9591489
Drug: Intramuscular (i.m.)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (i.m.) gonadotropins
Trial: 3348141
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg of sustained-release isosorbide dinitrate (ISDN)
Trial: 3348141
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg of sustained-release nifedipine
Trial: 30017873
Drug: Standardized dry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized dry ivy leaf extract syrup along with regular nasal irrigation for five days after nasal packing removal
Trial: 28223381
Drug: Gepotidacin 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gepotidacin 1,000 mg
Trial: 28223381
Drug: Gepotidacin 1,800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gepotidacin 1,800 mg
Trial: 24316325
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as Usual (TAU) at intervention sites
Trial: 17631801
Drug: High-dose Dinggui
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose Dinggui Oil (DGO-H, 1.2 g, 3 times daily)
Trial: 14996420
Drug: Paternal lymphocyte
RxNorm normalized name: Therapeutic allogeneic lymphocytes
DrugBank: Therapeutic allogeneic lymphocytes (DB17459)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paternal lymphocyte (PL) immunotherapy
Trial: 14996420
Drug: Autologous lymphocyte
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous lymphocyte (AL) immunotherapy
Trial: 14996420
Drug: Third party
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third party lymphocyte (TPL) immunotherapy
Trial: 9410372
Drug: Vaginal progesterone
RxNorm normalized name: progesterone Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal progesterone (Crinone) 90 mg per day
Trial: 9410372
Drug: Oral progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral progesterone (Utrogestan) 300 mg per day
Trial: 9410372
Drug: Oral progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral progesterone (Utrogestan)
Trial: 6785626
Drug: Test preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test preparation with lysozyme, papain and bacitracin
Trial: 31557351
Drug: T1D Exchange
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: T1D Exchange Registry (injection users)
Trial: 31557351
Drug: DPV Registry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPV Registry (injection users)
Trial: 28049170
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (500 µg twice daily) for 6 months
Trial: 25863853
Drug: Glaucoma group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glaucoma group (31 patients using at least 1 topical IOP-lowering medication)
Trial: 25863853
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (30 patients with no diagnosis of glaucoma or history of topical therapy usage)
Trial: 20354183
Drug: Anastrozole 1
RxNorm normalized name: anastrozole 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anastrozole 1 mg daily
Trial: 12611785
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy in addition to antidepressants and clinical management
Trial: 7983993
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B (0.5 mg/kg infused in 5% dextrose on alternate days for 14 doses)
Trial: 7983993
Drug: Sodium stibogluconate
RxNorm normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium stibogluconate (20 mg/kg in two divided doses daily for 40 days)
Trial: 26405263
Drug: UPA 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UPA 30 mg followed by placebo matching DSG for 20 days
Trial: 9099449
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg Lamisil (terbinafine) once daily for 15 days under fed condition
Trial: 31455425
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg intravenous (IV) zoledronic acid (ZA) in premenopausal women.
Trial: 27099272
Drug: 300 min/wk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 min/wk of aerobic exercise (high dose)
Trial: 21237568
Drug: S(+)‐ketamine (40mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S(+)‐ketamine (40mg per 70kg) infusion
Trial: 16441988
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (incision-curettage)
Trial: 9085319
Drug: Pharmacist recommendations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist recommendations to discontinue intravenous antibiotic therapy
Trial: 2932213
Drug: Oral high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral high-dose medroxyprogesterone acetate (HD-MPA)
Trial: 29474851
Drug: Greater dose
RxNorm normalized name: greater celandine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Greater dose of PA in control schools
Trial: 18813048
Drug: High-pressure injection
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-pressure injection (> 20 psi)
Trial: 18813048
Drug: Low-pressure injection
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-pressure injection (< 15 psi)
Trial: 11804979
Drug: Lytic monotherapy
RxNorm normalized name: Fytic acid
DrugBank: Phytic acid (DB14981)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lytic monotherapy
Trial: 10029609
Drug: Mesalamine tablets,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesalamine tablets, 4 g
Trial: 22956052
Drug: Statin group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin group (rosuvastatin 10 mg per day for 6 months)
Trial: 17261626
Drug: Brecanavir (BCV)
RxNorm normalized name: Brecanavir
DrugBank: Brecanavir (DB04887)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brecanavir (BCV) 50 to 600 mg with 100 mg ritonavir (RTV) every 12 hours or every 24 hours for 15 days
Trial: 17261626
Drug: Brecanavir (BCV)
RxNorm normalized name: Brecanavir
DrugBank: Brecanavir (DB04887)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brecanavir (BCV) 800 mg every 12 hours for 15 days
Trial: 17261626
Drug: Brecanavir (BCV)
RxNorm normalized name: Brecanavir
DrugBank: Brecanavir (DB04887)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brecanavir (BCV) with RTV 100 mg
Trial: 15578510
Drug: Peginterferon alfa‐2a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peginterferon alfa‐2a 180 mug/wk plus ribavirin 800 mg/day for 24 weeks
Trial: 23299384
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 olive oil capsules per day for 6 months)
Trial: 10674604
Drug: Quadruple anti-helicobacter
RxNorm normalized name: Helicobacter pylori
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadruple anti-helicobacter therapy
Trial: 9058216
Drug: Methylprednisolone (MPS),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (MPS), 1 g IV before CPB
Trial: 9058216
Drug: Aprotinin-full-dose protocol
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aprotinin-full-dose protocol
Trial: 2946016
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment effect (all groups)
Trial: 25017182
Drug: Olmesartan 40‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan 40‐mg tablet
Trial: 25017182
Drug: Coadministration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coadministration of rosuvastatin 20‐mg tablet and olmesartan 40‐mg tablet
Trial: 19875337
Drug: Both concurrent
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both concurrent and maintenance chemotherapy (SIM+SUB; n=154)
Trial: 19875337
Drug: Radiotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy with chemotherapy (SIM alone; n=118)
Trial: 14671423
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment followed by balloon treatment
Trial: 6225808
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of aztreonam
Trial: 6232015
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g of spectinomycin
Trial: 11242379
Drug: Brace treatment
RxNorm normalized name: Brace Relief
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brace treatment
Trial: 26555827
Drug: Brace treatment
RxNorm normalized name: Brace Relief
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brace treatment and Observation (crossover patients)
Trial: 26555827
Drug: Brace treatment
RxNorm normalized name: Brace Relief
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brace treatment and Observation (patients with Cobb angles ≥ 40 degrees)
Trial: 24783988
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy with lopinavir 400 mg and ritonavir 100 mg plus lamivudine 150 mg, both twice daily
Trial: 24783988
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy with lopinavir 400 mg and ritonavir 100 mg twice daily plus lamivudine or emtricitabine and another NRTI
Trial: 17556901
Drug: Omeprazole (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (10 or 20 mg)
Trial: 15043959
Drug: Nicotinamide (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotinamide (1.2 g/m2)
Trial: 12093324
Drug: Sertraline (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (50 to 150 mg/day)
Trial: 10184835
Drug: Fluoxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (20 to 60 mg/day)
Trial: 2523321
Drug: Danazol 600
RxNorm normalized name: Danazol
DrugBank: Danazol (DB01406)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Danazol 600 mg/day (increased to 800 mg/day if amenorrhea not achieved)
Trial: 31892920
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of GSC and NRT
Trial: 26256429
Drug: Levomilnacipran ER
RxNorm normalized name: levomilnacipran Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levomilnacipran ER 40 mg daily
Trial: 26256429
Drug: Levomilnacipran ER
RxNorm normalized name: levomilnacipran Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levomilnacipran ER 80 mg daily
Trial: 26256429
Drug: Levomilnacipran ER
RxNorm normalized name: levomilnacipran Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levomilnacipran ER 120 mg daily
Trial: 26256429
Drug: Levomilnacipran ER
RxNorm normalized name: levomilnacipran Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levomilnacipran ER (25-100 mg single dose)
Trial: 26256429
Drug: Levomilnacipran ER
RxNorm normalized name: levomilnacipran Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levomilnacipran ER (40, 80, 120 mg daily for 8 weeks)
Trial: 19998046
Drug: 1% sucralfate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% sucralfate lotion
Trial: 2764127
Drug: Naftidrofuryl, 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naftidrofuryl, 600 mg
Trial: 1097036
Drug: Control (normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (normal diet without fibre supplements)
Trial: 19663196
Drug: omeprasol 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: omeprasol 20 mg twice a day
Trial: 19663196
Drug: omeprasol 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: omeprasol 20 mg twice a day + BTD 240 mg twice a day
Trial: 10024613
Drug: Beta-carotene supplementation
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene supplementation (7.8 mg daily)
Trial: 7675298
Drug: Intravenous injections
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injections of methylcobalamin (MB12)
Trial: 7675298
Drug: Intravenous saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous saline injections (placebo trial)
Trial: 2254759
Drug: Continuous i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous i.v. infusion of recombinant human granulocyte-macrophage colony-stimulating factor
Trial: 28188670
Drug: PPV/CPA (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPV/CPA (100 mg/day for 7 days before vaccination)
Trial: 25995280
Drug: Food, Activity,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Food, Activity, and Breastfeeding intervention (FAB) and Combination intervention (Combo)
Trial: 10052663
Drug: Atropine (0.04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine (0.04 mg x kg(‐1))
Trial: 26580866
Drug: Fractional ablative
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractional ablative Er:YAG 2940-nm laser (FELR) with topical anti-aging and anti-pigment agents followed by ultrasound treatment
Trial: 26580866
Drug: Ultrasound treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound treatment following FELR and topical agents